{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=14", "query": { "condition": "Advanced Stage Solid Tumors", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 3078, "total_pages": 308, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:11:19.703Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Bladder Cancer", "HER2-positive Solid Tumor" ], "interventions": [ { "name": "PRS-343 in Combination with Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-08-21", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650348" }, { "nct_id": "NCT02913313", "title": "A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Broad Solid Tumor" ], "interventions": [ { "name": "BMS-986207", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2016-11-30", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 6, "location_summary": "Hackensack, New Jersey • New York, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02913313" }, { "nct_id": "NCT04165031", "title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3499446", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-11-28", "completion_date": "2020-10-30", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165031" }, { "nct_id": "NCT07524322", "title": "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "PIK3CA Mutation", "HER2- Negative Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor", "Hormone Receptor Positive Tumor", "Cervical Cancer" ], "interventions": [ { "name": "RGT-490", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regor Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2026-07-21", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 6, "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania • Houston, Texas + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07524322" }, { "nct_id": "NCT02301117", "title": "A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-01", "completion_date": "2019-06-19", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Duarte, California • Santa Monica, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301117" }, { "nct_id": "NCT02219724", "title": "A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "MOXR0916", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2014-08-12", "completion_date": "2019-08-18", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219724" }, { "nct_id": "NCT04608045", "title": "Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CPX-POM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CicloMed LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-05-19", "completion_date": "2023-04-30", "has_results": true, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04608045" }, { "nct_id": "NCT02799095", "title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ALKS 4230", "type": "DRUG" }, { "name": "ALKS 4230 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mural Oncology, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 243, "start_date": "2016-09-14", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 12, "location_summary": "Denver, Colorado • Port Saint Lucie, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799095" }, { "nct_id": "NCT00003207", "title": "Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "PSC 833", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "1998-03", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003207" }, { "nct_id": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Acute Lymphoblastic Leukemia", "Diffuse Large B Cell Lymphoma", "Triple Negative Breast Cancer Malignancies" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "PRGN-3007", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-01-25", "completion_date": "2024-04-18", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-11-15T13:11:19.703Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05694364" } ] }